Details up front: dizziness · five · mazdutide.
I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.
I have a working setup and a notebook, and I am prepared to be told that my setup is inadequate if that is the answer.
Which parts of this are load-bearing and which parts are habit?
Week 5 is day 35: on a four-week ladder that is week 1 of dose step 2, and — at the seven-day half-life this class runs on — 5 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 35 is exactly that point. That distinction is most of the question: at week 1 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Dizziness in a deficit is usually postural and usually volume-related. It is also the symptom on this list with the shortest path to something that needs assessing in person rather than posting about. Dose decisions are made under supervision, and nothing here is medical advice.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Four half-lives between steps, minimum. Work it out for your agent.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Stepping back is a normal adjustment, not a failure.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Slower costs time and nothing else. The ceiling is the same.
Escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
Concretely, the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Nothing here is medical advice, and research-use compounds are not approved for human use.
The top of the schedule is not the target. The working dose is.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.